头颈部早期黑色素瘤手术切除与生活质量的相关性
这项纵向前瞻性队列研究纳入56例在单一三级医疗中心接受分期切除术的头颈部Tis或T1a黑色素瘤患者,随访1年。结果显示,术后6个月和1年生活质量较基线改善,女性和65岁以下患者在基线时生活质量更差;作者认为这些结果可用于为该患者群体量身定制咨询。
要点
- 头颈部Tis/T1a黑色素瘤患者术后6个月和1年生活质量较基线改善。
- 基线时女性和65岁以下患者的生活质量评分更差。
- 性别差异随时间缩小,年龄差异持续至术后1年。
核心结论
- 术后6个月和1年生活质量的改善与早期头颈部黑色素瘤的手术切除相关,年轻和女性患者的生活质量更差,这些结果可用于为该患者群体量身定制咨询。
研究设计与样本
- 纵向前瞻性队列研究,纳入56例在单一三级医疗中心(纽约纪念斯隆凯特琳癌症中心)接受分期切除术的头颈部Tis或T1a黑色素瘤患者,招募时间为2016年6月1日至2017年2月28日,术后随访1年。
主要发现
- 共56例患者,其中女性24例(43%)、男性32例(57%),平均(范围)年龄67.2(32-88)岁,所有患者自我认同为白人。
- 围手术期问卷完成41份(73%),术后6个月完成49份(88%),术后1年完成41份(73%)。
- 基线时女性Skindex-16平均评分14.2(95%CI,9.1-21.9)、SCI平均评分57.2(95%CI,48.3-67.6),男性Skindex-16平均评分7.0(95%CI,4.8-10.3)、SCI平均评分73.5(95%CI,66.0-81.7);65岁以下者Skindex-16平均评分16.1(95%CI,9.8-26.4)、SCI平均评分53.2(95%CI,44.1-64.3),65岁及以上者Skindex-16平均评分7.1(95%CI,5.0-10.0)、SCI平均评分74.3(95%CI,67.7-81.6)。
- 基线时评分最差的条目为担心皮肤状况(Skindex-16)和担心未来皮肤癌(SCI)。
- Skindex-16情绪分量表评分从基线至术后1年改善最大(26.6 vs 15.3;P < .001),SCI外观分量表评分同样改善最大(64.0 vs 84.6;P < .001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Surgical excision is the standard-of-care treatment for Tis and T1a melanomas of the head and neck. Currently, however, the association of diagnosis and surgical treatment of these typically slowly progressive and nonfatal melanomas with a patient's health-related quality of life (HRQoL) is unknown. OBJECTIVE: To characterize and assess HRQoL in patients with Tis and T1a head and neck melanoma, evaluate changes in HRQoL over the surgical treatment course, and identify patient characteristics associated with lower HRQoL. DESIGN, SETTING, AND PARTICIPANTS: This longitudinal, prospective cohort study involved patients with Tis or T1a melanoma of the head and neck who underwent staged excision at a single tertiary care center (Memorial Sloan Kettering Cancer Center, New York, New York) and were recruited from June 1, 2016, to February 28, 2017. Patients were followed up for 1 year after their surgical procedure. Participants were asked to complete 2 patient-reported outcome measure questionnaires, Skindex-16 and Skin Cancer Index (SCI), at 4 time points: baseline, perioperative (1 to 2 weeks after surgery), and 6-month and 1-year follow-up. MAIN OUTCOMES AND MEASURES: Scores on the Skindex-16 and SCI questionnaires. RESULTS: In total, 56 patients were included in the study, among whom 24 (43%) were female and 32 (57%) were male, with a mean (range) age of 67.2 (32-88) years; all patients self-identified as white. Forty-one (73%) questionnaires at perioperative, 49 (88%) at 6-month postoperative, and 41 (73%) at 1-year postoperative time points were completed. At baseline, female patients and those younger than 65 years had statistically significantly worse HRQoL on the Skindex-16 questionnaire (mean score, 14.2 [95% CI, 9.1-21.9] and 16.1 [95% CI, 9.8-26.4]) and on the SCI questionnaire (mean score, 57.2 [95% CI, 48.3-67.6] and 53.2 [95% CI, 44.1-64.3]) compared with males (mean Skindex-16 score, 7.0 [95% CI, 4.8-10.3]; mean SCI score, 73.5 [95% CI, 66.0-81.7]) and those aged 65 years or older (mean Skindex-16 score 7.1 [95% CI, 5.0-10.0]; mean SCI score, 74.3 [95% CI, 67.7-81.6]). Questions that demonstrated the worst scores at baseline were worry about skin condition (Skindex-16) and worry about future skin cancers (SCI). The emotions subscale scores on the Skindex-16 questionnaire showed the greatest improvement from baseline to 1-year follow-up levels (26.6 vs 15.3; P < .001) and so did the appearance subscale scores on the SCI questionnaire (64.0 vs 84.6; P < .001). The score difference in HRQoL by sex diminished over time, whereas the score difference by age persisted through the first year. CONCLUSIONS AND RELEVANCE: Improvement in HRQoL at the 6-month and 1-year follow-up was associated with surgical excision in patients with early-stage head and neck melanoma, and younger and female patients experienced worse HRQoL. These results may be used in tailoring counseling for this patient population.
引用
- Mori S, Blank NR, Connolly KL, et al. Association of Quality of Life With Surgical Excision of Early-Stage Melanoma of the Head and Neck. JAMA Dermatol. 2019. PMID: 30422228. doi:10.1001/jamadermatol.2018.3409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。